The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type.

Chiara Tarantelli,Eleonora Cannas, Hillarie Ekeh,Carmelo Moscatello,Eugenio Gaudio,Luciano Cascione,Sara Napoli, Cesare Rech,Andrea Testa,Chiara Maniaci,Andrea Rinaldi,Emanuele Zucca,Anastasios Stathis,Alessio Ciulli,Francesco Bertoni

Exploration of targeted anti-tumor therapy（2021）

引用 2|浏览3

暂无评分

摘要

The BET degrader MZ1 had strong cytotoxic activity in all the ABC DLBCL cell lines that were tested, and, at least , it elicited more profound effects than BET inhibitors, and encourages further investigations.

查看译文

关键词

BET,bromodomain,bromodomain-containing protein 4,diffuse large B-cell lymphoma,epigenetics,immuno-oncology,lymphoma,proteolysis-targeting chimeras

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要